

Triastek, Eli Lilly explore 3D printing for oral drug delivery

July 14, 2022 | News

Triastek announces research collaboration with Lilly to explore the application of 3D printing technology in oral delivery of drugs



China-based startup Triastek has announced a collaboration with Eli Lilly and Company to leverage the advantages of 3D printing technology to enable precisely targeted and programmed release of drugs in specific regions of the GI tract.

According to the agreement, the project will focus on the targeted release of drugs in the intestine. Triastek will focus on two aspects: Firstly, conduct an in-depth study of excipient properties and process parameters to maintain drug stability throughout the formulation development and 3D printing process, as well as during drug release. Secondly, identify a unique three-dimensional structure dosage form design, that will permit programmed release of drugs in specific parts of the intestine, with the goal of improving the bioavailability of orally administered drugs.

Triastek is a 3D printing technology platform company, and its pioneering MED technology has versatile applications in solid dosage forms development and manufacturing. With the facilitation of this collaboration by Lilly China Innovation & Partnerships, Triastek will work with Lilly to explore novel solutions to the oral delivery of drugs.